Globally, cardiovascular disease remains a serious reason behind adverse outcomes in every individual. Myocardial infarction (MI) is the most current cardio-vascular disease within the Western world and results in heart failure once its management is improper. It has serious consequences in mortality, morbidity, and value to society. It has a damaging potential for heart cells and suddenly reduces the flow rate, a clinical condition referred to as heart dysfunction that may accomplish heart condition. Myocardial infarction is outlined as sudden ischemic death of myocardial tissue. Within the clinical context, myocardial infarction is typically because of thrombotic occlusion of a coronary vessel caused by rupture of a vulnerable plaque. The adult mammalian heart has negligible regenerative capability, so the infracted cardiac muscle heals through formation of a scar. Activation of the renin-angiotensin-aldosterone system and release of growth factor-? induce conversion of fibroblasts into myofibroblasts, promoting deposition of extracellular matrix proteins. This review discusses the underlying pathophysiology, evolving views on diagnosing, risk stratification, and pharmacologic management of myocardial infarction. Moreover, we tend to discuss the treatment ways like anti-thrombic therapy and implications of pathophysiological insights in design, and implementation of recent promising therapeutic approaches for patients with myocardial infarction. New treatments can still emerge, however, the best challenge is going to be to effectively implement preventive actions altogether high-risk people and to expand the delivery of acute treatment certain all patients.